IP Briefs: Demystifying the Patent Reform Act and its Impact on Company IP Strategy - IP stakeholders should focus on both patent procurement and enforcement strategies to maintain harmony between IP

ADVERTISEMENT

IP Briefs: Demystifying the Patent Reform Act and its Impact on Company IP Strategy
IP stakeholders should focus on both patent procurement and enforcement strategies to maintain harmony between IP assets and company business strategy


BioPharm International
Volume 20, Issue 1

4. American Bar Association, Section of Intellectual Property Law, A Section White Paper: Agenda for 21st Century Patent Reform (September 16, 2005); Patent Act of 2005: Hearings on H.R. 2795 Before the Subcomm. on Courts, the Internet and Intellectual Property of the House Judiciary Comm., 109th Cong. (2005) (statement of Gary Griswold, Past President of the American Intellectual Property Law Association); Hearings on Patent Law Reform: Patent Injunctions and Damages Before the Subcomm. on Intellectual Property of the Senate Judiciary Comm., 109th Cong. (2005) (statement of J. Jeffrey Hawley, President, Intellectual Property Owners Association); Hearings on An Amendment in the Nature of a Substitute to H.R. 2795, the Patent Reform Act of 2005 Before the Subcomm. on Courts, the Internet and Intellectual Property of the House Judiciary Comm., 109th Cong. (2005) (statement of Robert B. Chess, Executive Chairman, Nektar Therapeutics, Testifying on Behalf of The Biotechnology Industry Organization); Hearings on An Amendment in the Nature of a Substitute to H.R. 2795, the Patent Reform Act of 2005 Before the Subcomm. on Courts, the Internet and Intellectual Property of the House Judiciary Comm., 109th Cong. (2005) (statement of Philip S. Johnson, Chief Patent Counsel, Johnson & Johnson, Testifying on Behalf of The Pharmaceutical Research and Manufacturers of America).

5. H.R. 2795. 109th Cong. 6 (2005).

6. Coalition for Patent Reform, Modifications to An Amendment in the Nature of a Substitute to H.R. 2795. 109th Cong. Coalition Print 2005.

7. Hearing on An Amendment in the Nature of a Substitute to H.R. 2795, the Patent Reform Act of 2005, supra note 5 (statement of Philip S. Johnson).

8. Georgia-Pacific Corp. v. United States Plywood Corp., 318 F.Supp. 1116, 1120 (S.D.N.Y. 1970).

9. Imonex Services, Inc. v. W. H. Munzprufer Dietmar Trenner GmbH, 408 F.3d 1374 (Fed. Cir. 2005).

10. H.R. 2795. 109th Cong. 6 (2005).

11. Amendment in the Nature of a Substitute to H.R. 2795, 109th Cong. 6 (July 26, 2005).

12. H.R. 2795, 109th Cong. 4 (2005).

13 See id. 5.

14. Id.

15. See id. 9.

16. Id.

17. Carella v. Starlight Arcdhery & Pro Line Co., 804 F.2d 135 (Fed. Cir. 1986).

18. See id. 9.

19. See id. 8.

20. See id. 4.

21. See id. 3.

22. Hearings on An Amendment in the Nature of a Substitute to H.R. 2795, the Patent Reform Act of 2005, supra note 5 (statement of Robert B. Chess); Hearings on An Amendment in the Nature of a Substitute to H.R. 2795, the Patent Reform Act of 2005, supra note 5 (statement of Philip S. Johnson).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here